Literature DB >> 20626734

Extended spectrum beta-lactamase-producing bacteria and Clostridium difficile in patients with pouchitis.

S D McLaughlin1, S K Clark, C H Roberts, Z L Perry-Woodford, P P Tekkis, P J Ciclitira, R J Nicholls.   

Abstract

BACKGROUND: Treatment with fluoroquinolones is associated with the development of Clostridium difficile and extended spectrum beta-lactamase-producing bacteria (ESBL). Clostridium difficile and ESBL are resistant to many antibiotics and each may cause pouchitis after restorative proctocolectomy (RPC) refractory to empirical antibiotic therapy. AIM: To assess the prevalence and establish risk factors for the development of ESBL and Clostridium difficile toxins (CDT) in RPC patients with recurrent or refractory pouchitis under follow-up at our institution over a 1-year period.
METHOD: An enzyme-linked immunosorbent assay was used to detect CDT and a culture technique was used to identity ESBL in faecal samples. All patients had previously received fluoroquinolone treatment.
RESULTS: Forty-eight patients (35 (74%) men; median age 42 years) underwent testing at a median interval from RPC of 8 (range 1-25) years. No patient had a positive CDT result, but ESBL bacteria were identified in 16 (33%) samples. ESBL positivity was significantly related to prepouch ileitis (P = 0.035) and maintenance antibiotic therapy (P = 0.039).
CONCLUSIONS: Extended spectrum beta-lactamase, but not CDT, is a common finding in faecal samples from patients with recurrent or refractory pouchitis. Treatment with maintenance antibiotics and prepouch ileitis are risk factors for developing ESBL-producing bacteria. 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20626734     DOI: 10.1111/j.1365-2036.2010.04401.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  5 in total

Review 1.  Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.

Authors:  Bo Shen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-04-17       Impact factor: 46.802

2.  Obesity Is Associated with Decreased Risk of Clostridium difficile Infection in Hospitalized Patients with Pouchitis.

Authors:  Falgun Gosai; Fahrettin Covut; Mohammad Alomari; Asif Hitawala; Amandeep Singh; Gaurav Kisangani; Rocio Lopez; Bo Shen
Journal:  Dig Dis Sci       Date:  2019-10-15       Impact factor: 3.199

3.  Prevalence and incidence of antimicrobial-resistant organisms among hospitalized inflammatory bowel disease patients.

Authors:  Alon Vaisman; Kevin Pivovarov; Allison McGeer; Barbara Willey; Bjug Borgundvaag; Vanessa Porter; Piraveina Gnanasuntharam; Yanliang Wei; Geoffrey C Nguyen
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

Review 4.  Review article: the pathogenesis of pouchitis.

Authors:  K M Schieffer; E D Williams; G S Yochum; W A Koltun
Journal:  Aliment Pharmacol Ther       Date:  2016-08-24       Impact factor: 8.171

5.  Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis.

Authors:  J Landy; A W Walker; J V Li; H O Al-Hassi; E Ronde; N R English; E R Mann; D Bernardo; S D McLaughlin; J Parkhill; P J Ciclitira; S K Clark; S C Knight; A L Hart
Journal:  Sci Rep       Date:  2015-08-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.